| Drug Name: | Imatinib |
|---|
| Drug Class: | Tyrosine kinase inhibitor |
|---|
| Mechanism of Action: | - Inhibits the activity of BCR-ABL tyrosine kinase
- Inhibits the activity of c-KIT and PDGFRA tyrosine kinases
|
|---|
| Use: | - Treatment of chronic myeloid leukemia (CML)
- Treatment of gastrointestinal stromal tumors (GISTs)
- Treatment of dermatofibrosarcoma protuberans (DFSP)
|
|---|
| Side Effects: | - Nausea and vomiting
- Diarrhea
- Muscle cramps
- Fluid retention
- Fatigue
- Skin rash
|
|---|
| Contraindications: | - Hypersensitivity to imatinib
- Pregnancy and breastfeeding
- Severe liver or kidney disease
|
|---|
| Specialty: | - Oncology
- Hematology
- Dermatology
|
|---|